Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Australian Technology
Innovation Fund Limited
Prospectus presentation
Your entry into the lucrative biotech market
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The biotech market• Biotechnology is a highly
specialised sector offering excellent investment opportunities to those able to identify projects with global commercialisation potential.
• ATIF identifies and develops biotechnology projects of the highest potential in Australia and offshore. This is your opportunity to own a
share of the lucrative biotech market.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The biotech market• Traditionally, there is a lack of
suitable entities in the biotech market with:– The complex skills required to
target appropriate biotechnology investments
– The ability to cost-effectively manage the risk profile of a specialised biotechnology portfolio.
ATIF has the experienced management and complex skills required for success in this field.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
About ATIF• ATIF holds an attractive and
diverse asset base through its interests in three Australian biotechnology companies:– CBio Limited (16.37%)– Psiron Limited (15.93%)– Analytica Limited (14.71%)
ATIF provides assistance to these companies to achieve their commercial objectives.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
About ATIF• Directors
– Dr Wolf Hanisch – more than 20 years experience in the biotech industry, including a $45 million IPO for Idec Pharmaceuticals.
– Mr Stephen Jones – corporate recovery and turnaround specialist. Former member of Qld Govt’s Queensland Innovation Council.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
About ATIF• Directors cont…
– Dr Michael Monsour – medical practitioner with business interests in QLD medical centres.
ATIF has specialist expertise in biotechnology and capital
financing sectors – a key ATIF advantage.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
About ATIF• ATIF’s Board and Management
have high-level scientific and financial experience and are intending ATIF to become Australia’s leading diversified biotechnology company.
• ATIF intends to retain its focus on biotechnology investment, and has formulated the following business plan.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
ATIF Business Plan1. Fulfil own working capital
needs from revenues raised through specialist corporate advisory to biotech sector.
2. Effective ongoing management of existing interests.
3. Assisting ATIF investments in achieving product development and funding outcomes.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
ATIF Business Plan4. Identifying new investment
opportunities and industry alliances both in Australia and overseas.
5. Integrating acquisitions and developing well-timed “spin off” IPO opportunities.
The ATIF Business Plan gives a clear path for success in the
biotech sector.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
ATIF’s Investments
• ATIF has stringent criteria used in selecting current and future investments:– Product-focussed investment
approach– Risk management– Technical competence and
skilled hands-on management– IP protection and product-base
diversification
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
ATIF’s Investments
• ATIF’s investments are diversified among a variety of complementary biotech areas:– CBio Ltd
• Immune System modulation
– Psiron Ltd• Anti-inflammation, Anti-cancer
– Analytica Ltd • Diagnostics
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
CBio Ltd• Unlisted Australian Public Company
who owns patent for hormone Early Pregnancy Factor (EPF).
• EPF has patented applications in: – auto-immune disease market (MS
and R. Arthritis) – organ rejection – burns treatment– cancer (diagnosis and therapy)– being prepared for listing “04-05”
on appropriate international exchange.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Psiron Ltd
• Australian Public Company which listed on ASX.
• Operates in biotech/healthcare segment and has investments in– Analytica Ltd.– CBio
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Psiron Ltd
• Therapeutics interests are in anti-cancer and anti-inflammation such as:– SPLA2 anti-inflammation
• New generation anti-inflammatory
– Psorafin psoriasis• Psiron owns worldwide rights to
the patented Sorafin compound (treatment for Psoriasis) under and exclusive license.
• Psoriasis is one of the world’s most common skin diseases.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Analytica Ltd
• Australian public company listed on the ASX.
• Diagnostics business with current annual sales revenues of approximately $1.2 million.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The ATIF advantage
Established to take advantage of value-priced investment
opportunities in the biotechnology sector, ATIF
offers industry-specific expertise and an established
and diverse portfolio of biomedical projects and
patents.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The ATIF advantage
• ATIF has the specialist expertise to surmount traditional biotech investment barriers.
• ATIF fills a void in the investment sector.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The ATIF share offer
• 5 million fully-paid shares in ATIF Ltd are on offer at an issue price of $1.00 each.
• Minimum requirement 2000 shares at $1.00 per share, or greater numbers in multiples of 1000 thereafter.
• Applications accepted from 23 October 2002 until 20 December 2002.
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The ATIF share offer
• Why Invest in ATIF?– Excellent capital growth
opportunities– Exclusive preferential access
to additional investment opportunities, including underwriting and sub-underwriting agreements, IPOs and other share issues
– The benefit of diversification in the biotechnology sector
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
The ATIF share offer
By investing in ATIF, shareholders: – Gain ownership of an
excellent capital growth opportunity
– Gain access to key “deal maker” positions resulting from ATIF initiatives
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Your opportunity
• This is your opportunity to invest in an attractive and diverse biotechnology asset base, and benefit from:– Diversity through ATIF’s four
investments for price of one– Low entry price for new
investments– Strong Board and Management
team with real experience
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Your opportunity
• Further information for your perusal:– Prospectus for Australian
Technology Innovation Fund Limited share offer
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Your questions answered
• If you have any questions or would like a copy of the complete prospectus, contact us at ATIF on:Ph. 07 3371 3000Fax. 07 3371 3011Email. [email protected] BX 3104South Brisbane BCQLD 4101 Australia
Australian Technology Innovation Fund LimitedYour entry into the lucrative biotech market
Your entry into the lucrative
biotech market